Holen Sie sich die Stockscreener-App
175.84
2.55%
-4.60
Handel nachbörslich:
175.84
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Marshall Wace LLP Boosts Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen (SUPN) gains Health Canada NOC for ZURZUVAE in postpartum depression treatment - Stock Titan
Amundi Cuts Position in Biogen Inc. $BIIB - MarketBeat
Eisai and Biogen's LEQEMBI® Added to China's Commercial Insurance Innovative Drug List, Enhancing Access to Alzheimer's Treatment - Quiver Quantitative
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List - Biogen
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List - GlobeNewswire Inc.
Biogen (BIIB): Assessing Valuation After Promising New Zorevunersen Data in Dravet Syndrome - simplywall.st
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business? - The Globe and Mail
Is Biogen Stock Outperforming the Dow? - Barchart.com
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025 - marketscreener.com
Invesco Ltd. Increases Stock Position in Biogen Inc. $BIIB - MarketBeat
Lido Advisors LLC Has $647,000 Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stake Reduced by Schroder Investment Management Group - MarketBeat
Biogen Inc. $BIIB Shares Bought by Guggenheim Capital LLC - MarketBeat
First Trust Advisors LP Acquires 212,403 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen (BIIB) Advances Potential Treatment for Dravet Syndrome w - GuruFocus
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
BIIB: Promising Data for Biogen's Zorevunersen in Dravet Syndrome Treatment - GuruFocus
Stoke Therapeutics and Biogen present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
Stoke, Biogen Present Positive Long-Term Results For Zorevunersen In Dravet Syndrome - Nasdaq
Biogen and Stoke Therapeutics present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
Stoke Therapeutics, Inc. and Biogen Present Data on Zorevunersen at AES 2025 - TradingView
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - The Manila Times
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - Business Wire
American Century Companies Inc. Increases Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Stoke Therapeutics: A Long-Term Biotech Growth PlayWhy I Assign A Hold Rating (STOK) - Seeking Alpha
Key facts: Biogen's Alzheimer's drug delays progression by 30%; CEO boosts shares - TradingView
New York State Common Retirement Fund Increases Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Shares New Leqembi Data on Slower Alzheimer's Progression, Injection Option - marketscreener.com
Biosimilars and Biologics Market is expected to reach US$ - openPR.com
Arrowstreet Capital Limited Partnership Grows Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Should New LEQEMBI Data and Subcutaneous Option Shift the Risk Profile for Biogen (BIIB) Investors? - simplywall.st
Biogen (BIIB) Reports Promising Lecanemab Findings for Alzheimer's Treatment - GuruFocus
Eisai and Biogen Present Long-Term LEQEMBI Data Indicating Potential Delay in Alzheimer's Disease Progression by Up to 8.3 Years - Quiver Quantitative
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Con - StreetInsider
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 - PR Newswire
Biogen’s strategic turn to New Ventures - BioCentury
BIIB: Felzartamab and lupus assets advance in late-stage trials, targeting major unmet needs - TradingView
Mackenzie Financial Corp Boosts Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stake Reduced by Fisher Asset Management LLC - MarketBeat
Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference - marketscreener.com
Biogen (BIIB) Sees Promising Lecanemab Results in Alzheimer's Tr - GuruFocus
Lecanemab shows effect on Alzheimer’s biomarkers in new study By Investing.com - Investing.com India
Biogen (BIIB): Assessing Valuation After Recent Share Price Gains - Yahoo Finance
Lecanemab shows effect on Alzheimer’s biomarkers in new study - Investing.com
Eisai and Biogen Present New Findings on Lecanemab's Effects on Alzheimer’s Disease at CTAD Conference - Quiver Quantitative
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF - PR Newswire
I Remember Aduhelm. The Return of Roche in Alzheimer’s Is a Turning Point - BioSpace
Biogen Inc.: Financial Data Forecasts Estimates and Expectations | BIIB | US09062X1037 - marketscreener.com
Does Biogen’s Valuation Stack Up After Recent Alzheimer’s Regulatory Updates? - simplywall.st
Multiple Sclerosis Therapeutics Market Growth Accelerates - openPR.com
What insider trading reveals about Biogen Inc. stockTrade Signal Summary & Long-Term Safe Investment Plans - Newser
Biogen Inc.: Dividend historical data and projections - marketscreener.com
Norges Bank Acquires Shares of 2,264,177 Biogen Inc. $BIIB - MarketBeat
Quadrant Capital Group LLC Has $1.03 Million Position in Biogen Inc. $BIIB - MarketBeat
Will Biogen Inc. stock deliver shareholder valueJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - Newser
Transforming Growth Factor Beta Pipeline Drugs Insights Report - openPR.com
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Me - pharmiweb.com
Biogen Inc (BIIB) Stock Price Prediction: 2025, 2026, 2030 - Benzinga
Biogen and Stoke Therapeutics Present Promising Zorevunersen Data for Dravet Syndrome at 2025 American Epilepsy Society Annual Meeting - Quiver Quantitative
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Biogen
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Business Wire
Skandinaviska Enskilda Banken AB publ Acquires 20,500 Shares of Biogen Inc. $BIIB - MarketBeat
Neuberger Berman Group LLC Has $1.40 Million Position in Biogen Inc. $BIIB - MarketBeat
Russell Investments Group Ltd. Increases Stock Position in Biogen Inc. $BIIB - MarketBeat
Intech Investment Management LLC Sells 2,973 Shares of Biogen Inc. $BIIB - MarketBeat
Employees Retirement System of Texas Takes Position in Biogen Inc. $BIIB - MarketBeat
A Look at Biogen's Valuation as It Expands Immunology Pipeline With Dayra Therapeutics Collaboration - simplywall.st
Patient Capital Management LLC Trims Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Vinva Investment Management Ltd Purchases Shares of 58,862 Biogen Inc. $BIIB - MarketBeat
BIIBBiogen Inc Stock Price and Quote - Finviz
Nvidia, Microsoft, Apple, Zillow, Biogen: What brokers said this week - Proactive Investors
Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot - Sahm
1.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):